Stay updated on Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.8%
    Check dated 2025-05-29T06:11:46.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-04-30T16:56:02.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page has undergone significant content removal regarding the study of Camidanlumab Tesirine (ADCT-301) for relapsed Hodgkin Lymphoma, including details about the study's purpose, design, and participant criteria. A new revision number has been added.
    Difference
    25%
    Check dated 2025-04-16T12:38:31.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T05:27:53.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-04-01T22:37:11.000Z thumbnail image
  8. Check
    97 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.7%
    Check dated 2025-02-24T20:20:04.000Z thumbnail image

Stay in the know with updates to Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Camidanlumab Tesirine in Hodgkin Lymphoma Clinical Trial page.